- Home
- XFOR vs PSQH Comparison
XFOR vs PSQH Comparison
Compare XFOR & PSQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- PSQH
- Stock Information
- Founded
- XFOR 2014
- PSQH 2021
- Country
- XFOR United States
- PSQH United States
- Employees
- XFOR N/A
- PSQH N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- PSQH Advertising
- Sector
- XFOR Health Care
- PSQH Consumer Discretionary
- Exchange
- XFOR Nasdaq
- PSQH Nasdaq
- Market Cap
- XFOR 118.4M
- PSQH N/A
- IPO Year
- XFOR N/A
- PSQH N/A
- Fundamental
- Price
- XFOR $0.25
- PSQH $2.34
- Analyst Decision
- XFOR Strong Buy
- PSQH Strong Buy
- Analyst Count
- XFOR 3
- PSQH 2
- Target Price
- XFOR $2.83
- PSQH $6.00
- AVG Volume (30 Days)
- XFOR 1.7M
- PSQH 588.8K
- Earning Date
- XFOR 03-25-2025
- PSQH 03-13-2025
- Dividend Yield
- XFOR N/A
- PSQH N/A
- EPS Growth
- XFOR N/A
- PSQH N/A
- EPS
- XFOR N/A
- PSQH N/A
- Revenue
- XFOR $2,557,000.00
- PSQH $23,199,434.00
- Revenue This Year
- XFOR $397.34
- PSQH $73.40
- Revenue Next Year
- XFOR $231.16
- PSQH $71.26
- P/E Ratio
- XFOR N/A
- PSQH N/A
- Revenue Growth
- XFOR N/A
- PSQH 308.01
- 52 Week Low
- XFOR $0.24
- PSQH $2.00
- 52 Week High
- XFOR $1.60
- PSQH $7.77
- Technical
- Relative Strength Index (RSI)
- XFOR 30.93
- PSQH 33.82
- Support Level
- XFOR $0.24
- PSQH $2.58
- Resistance Level
- XFOR $0.29
- PSQH $2.78
- Average True Range (ATR)
- XFOR 0.03
- PSQH 0.19
- MACD
- XFOR 0.00
- PSQH 0.02
- Stochastic Oscillator
- XFOR 6.19
- PSQH 18.18
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.